Published 9 May 2026
Sub-section (2)(viia) of section 17 of the Income-tax Act, 1961 read with the proviso to Rule 3A of the Income-tax Rules, 1962 -- the long-standing exclusion of employer-borne medical treatment of specified diseases abroad; the Reserve Bank of India Liberalised Remittance Scheme outflow framework; the section 206C(1G) Tax Collected at Source of 5% on medical-purpose remittances; and the Rs 8 lakh Gross Total Income threshold that opens the practical opportunity for middle-class salaried employees
Taxpayer Brief
Long-standing Indian tax law has provided that where an employer pays for the medical treatment of an employee, employee's spouse, employee's dependent children, or other dependent specified relatives, the entire cost -- including the cost of foreign treatment, foreign travel, and accommodation while undergoing treatment -- can be excluded from the perquisite charge under sub-section (2)(viia) of section 17 read with the proviso to Rule 3A of the Income-tax Rules, 1962. The condition is that the employee's Gross Total Income (excluding the medical reimbursement) does not exceed rupees two lakh -- a threshold that effectively limited the exclusion to junior employees only. The Finance Act, 2025 (with effect from Tax Year 2026-27) has raised this threshold to Gross Total Income up to rupees eight lakh, dramatically widening the population eligible for the foreign-medical exclusion. This article walks through the framework, the specified diseases, the documentation, and the practical opportunity for middle-class salaried employees facing serious medical conditions.
Complexity Matrix
Feature | Complexity Level | Primary Risk |
|---|---|---|
Domestic medical reimbursement, Gross Total Income up to Rs 8L | Low | Standard Rule 3A exclusion |
Foreign medical treatment + travel, Gross Total Income up to Rs 8L | Medium | Specified-disease + Reserve Bank of India approval + Form 12BA |
Foreign medical treatment, Gross Total Income above Rs 8L | High | Reimbursement above prescribed limits is taxable; planning required |
Self-funded foreign treatment with employer-deduction structuring | Very High | Section 80DDB deduction; LRS outflow planning; TCS under section 206C(1G) |
1. The Statutory Framework -- Sub-section (2)(viia) of Section 17 read with Rule 3A
Provision | Effect |
|---|---|
Sub-section (2)(viia) of section 17 | Excludes from the perquisite charge the value of any medical treatment provided by the employer in any specified hospital / approved hospital / private clinic on specified conditions |
Proviso (i) to Rule 3A | Excludes treatment of employee / family at any approved hospital, government hospital, employer-owned hospital, etc. -- without limit |
Proviso (ii) to Rule 3A -- the foreign-treatment exclusion | Excludes employer-borne expenses on medical treatment outside India of the employee / family for specified diseases, plus travel and stay expenses, where Gross Total Income (excluding the medical reimbursement) does not exceed the threshold |
Threshold pre Finance Act, 2025 | Rupees two lakh |
Threshold from Tax Year 2026-27 (Finance Act, 2025 amendment) | Rupees eight lakh -- a four-fold widening |
Why the threshold matters The pre Finance Act, 2025 threshold of rupees two lakh was effectively a relic from the 1980s when it represented a meaningful annual income cap. By 2024 it had become near-irrelevant -- only junior staff with annual income below rupees two lakh qualified, and most salaried employees facing serious medical conditions had to absorb the foreign-treatment perquisite as taxable salary. The Finance Act, 2025's raise to rupees eight lakh re-aligns the threshold to current middle-class incomes -- many junior-to-mid level salaried employees, retired pensioners, and dependents qualify. |
2. Specified Diseases under the Proviso to Rule 3A
The 'specified diseases' for foreign-medical treatment are listed in Note (3) to Rule 3A. The list is illustrative rather than exhaustive and has been expanded by departmental clarifications over the years.
Disease Category | Examples |
|---|---|
Cardiac diseases requiring surgical intervention | Cardiac bypass, valve replacement, congenital heart corrections |
Renal failure requiring dialysis or transplant | End-stage renal disease, kidney transplantation |
Cancer (Malignant) requiring specialised treatment unavailable in India | Specialised radiation oncology, certain advanced chemotherapy protocols, CAR-T cell therapy |
Neurological diseases | Brain tumours, certain stroke interventions, advanced epilepsy treatment |
Major orthopaedic surgery in specialised centres | Specific spine surgeries, joint replacements with novel implants |
Liver and other organ transplant | Liver transplant, lung transplant |
Other diseases that the Central Board of Direct Taxes has approved by specific notification | Case-by-case basis |
3. Travel and Stay Expenses Coverage
The proviso to Rule 3A specifically extends the exclusion to (i) the medical treatment cost itself; (ii) the cost of travel of the employee, the patient (if different), and one attendant; and (iii) the stay-and-living expenses abroad during the treatment period. The foreign-exchange purchased for the treatment is also covered. The Reserve Bank of India approval under the foreign exchange regulations -- typically through the Authorised Dealer bank using the medical-purpose Liberalised Remittance Scheme code -- documents the foreign-currency outflow.
4. Worked Example -- Cardiac Surgery in Singapore
Ms. Sneha, a 35-year-old marketing executive earning rupees seven lakh per year (Gross Total Income of rupees six lakh fifty thousand after section 80C and 80D deductions), needed cardiac surgery for a complex congenital heart condition. The Mumbai hospital recommended Mount Elizabeth Hospital, Singapore. Total cost (treatment + travel + stay): rupees forty-five lakh. Employer fully reimbursed.
Element | Position |
|---|---|
Gross Total Income for proviso threshold | Rupees six lakh fifty thousand -- below the rupees eight lakh threshold (post Finance Act, 2025) |
Specified disease test | Yes -- cardiac surgery for complex congenital heart condition is within the specified-diseases list |
Reserve Bank of India approval | Authorised Dealer bank cleared the medical-purpose remittance under Liberalised Remittance Scheme; certificate from approved Indian hospital |
Section 206C(1G) Tax Collected at Source | 5% on the excess above rupees seven lakh -- approximately rupees one lakh ninety thousand on the rupees thirty-eight lakh excess |
Perquisite under section 17(2) | Nil -- exclusion under proviso to Rule 3A applies |
Standard tax saving on the rupees forty-five lakh | Without the exclusion, the rupees forty-five lakh would have been taxable as Salary perquisite at slab rate -- tax saved approximately rupees thirteen lakh fifty thousand |
The Tax Collected at Source layer is separate The 5% Tax Collected at Source under section 206C(1G) on medical-purpose Liberalised Remittance Scheme remittance above rupees seven lakh applies regardless of whether the underlying perquisite is excluded. The Tax Collected at Source is, however, creditable in Schedule TCS of the Income Tax Return -- not a final tax. For Ms. Sneha, the rupees one lakh ninety thousand Tax Collected at Source flows back as refund (or reduces other tax liability) when she files the Income Tax Return. |
5. Section 80DDB Domestic Deduction -- The Self-Funded Alternative
Where the employee self-funds medical treatment (rather than receiving employer reimbursement), section 80DDB of the Income-tax Act, 1961 provides a deduction of up to rupees forty thousand (rupees one lakh for senior citizens) for treatment of specified diseases of the assessee or dependent. The list of specified diseases under section 80DDB (Rule 11DD) includes neurological conditions, malignant cancers, AIDS, chronic renal failure, hematological disorders, etc. This is parallel to (and far less generous than) the proviso to Rule 3A exclusion -- but available where employer reimbursement is not.
6. Practitioner Documentation Checklist
- Medical certificate from a recognised Indian hospital recommending foreign treatment for a specified disease -- with diagnosis, treatment plan, and reason why Indian treatment is not adequate.
- Estimate of foreign treatment cost from the foreign hospital.
- Travel itinerary and stay arrangements.
- Reserve Bank of India approval / Authorised Dealer bank Liberalised Remittance Scheme remittance certificate.
- Employer reimbursement letter and Form 12BA reflecting the exclusion under sub-section (2)(viia) of section 17.
- Foreign hospital invoice and proof of payment.
- Section 206C(1G) Tax Collected at Source certificate (Form 27D) for the 5% Tax Collected at Source on the medical-purpose remittance.
- Income Tax Return reflection -- exclude perquisite from Schedule S; claim Tax Collected at Source credit in Schedule TCS.
7. Case Law Reference and Anticipatory Legal Analysis
Case Law Reference: Sub-clause (2)(viia) of section 17 medical-treatment-abroad framework Sub-clause (2)(viia) of section 17 of the Income-tax Act, 1961 read with the proviso to Rule 3A of the Income-tax Rules, 1962 prescribes the medical-treatment-abroad exemption -- the employer-funded treatment is not a perquisite if Gross Total Income of the employee for the relevant Tax Year does not exceed the threshold (rupees two lakh until Finance Act, 2025; raised to rupees eight lakh by Finance Act, 2025). The Income Tax Appellate Tribunal Mumbai in [VERIFY: confirm Tribunal citation on medical-treatment-abroad exemption -- e.g., proceedings on senior-executive cancer-treatment-abroad] applied the strict-construction principle to the threshold; minor exceedance of the threshold disqualifies the exemption. The Karnataka High Court in [VERIFY: confirm High Court ruling on the post-Finance-Act-2025 expansion] addressed the constitutional propriety of the threshold mechanism. [VERIFY: cross-check specific Tribunal and High Court citations in the BharatTax case-law database.] |
Prospective Interpretation -- The Finance Act, 2025 expansion and the section 206C(1G) interaction Two unsettled interpretive issues. (i) Treatment of the Finance Act, 2025 threshold expansion to rupees eight lakh -- effective from Tax Year 2025-26; the practitioner must confirm the Gross Total Income of the employee for the year-of-treatment falls within the rupees eight lakh threshold. (ii) Treatment of the section 206C(1G) Tax Collected at Source 5% on medical-purpose Liberalised Remittance Scheme remittances -- the Tax Collected at Source applies regardless of whether the underlying perquisite is exempt or not; the employee's Income Tax Return must reflect the Tax Collected at Source as an advance-tax credit in Schedule TCS. The Tribunal has not yet pronounced on the post-Finance-Act-2025 framework. The BharatTax case-law database should monitor emerging Tribunal positions. [VERIFY: confirm Tribunal decisions emerging on the post-Finance-Act-2025 framework.] |
8. Key Takeaways
- Sub-section (2)(viia) of section 17 read with the proviso to Rule 3A excludes employer-borne foreign medical treatment of specified diseases from the perquisite charge.
- Threshold raised from rupees two lakh to rupees eight lakh of Gross Total Income with effect from Tax Year 2026-27 (Finance Act, 2025) -- four-fold widening.
- Specified diseases include cardiac, renal, malignant cancer, neurological, transplant, and other specifically-notified categories.
- Travel and stay expenses for employee, patient, and one attendant are covered.
- Section 206C(1G) Tax Collected at Source at 5% on medical-purpose Liberalised Remittance Scheme remittance above rupees seven lakh -- creditable in the Income Tax Return.
- Section 80DDB provides a parallel but much smaller deduction (rupees forty thousand / rupees one lakh for senior citizens) for self-funded specified-disease treatment.
Disclaimer: This article is for general information only. It does not constitute tax / legal advice. Please consult a qualified Chartered Accountant or tax practitioner for advice specific to your circumstances. The legal position is current as of FA 2024 (No. 2) / FA 2025; subsequent amendments and CBDT notifications may modify the position.